Danaher (NYSE:DHR) Stock Price Expected to Rise, Evercore Analyst Says

Danaher (NYSE:DHR) had its target price raised by equities researchers at Evercore from $225.00 to $232.00 in a research note issued to investors on Tuesday,MarketScreener reports. The brokerage currently has an “outperform” rating on the conglomerate’s stock. Evercore’s price target would indicate a potential upside of 26.01% from the stock’s previous close.

Other equities research analysts have also issued research reports about the stock. Jefferies Financial Group reaffirmed a “buy” rating and issued a $245.00 target price on shares of Danaher in a report on Tuesday. Guggenheim lowered their target price on shares of Danaher from $275.00 to $235.00 and set a “buy” rating on the stock in a report on Wednesday. TD Cowen lowered their target price on shares of Danaher from $245.00 to $240.00 and set a “buy” rating on the stock in a report on Wednesday. Barclays lowered their target price on shares of Danaher from $250.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 14th. Finally, Argus set a $265.00 target price on shares of Danaher in a report on Wednesday, January 14th. Seventeen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, Danaher has a consensus rating of “Moderate Buy” and a consensus price target of $243.20.

Danaher Trading Down 5.4%

Shares of Danaher stock opened at $184.11 on Tuesday. The firm has a market capitalization of $130.30 billion, a PE ratio of 35.61, a price-to-earnings-growth ratio of 2.64 and a beta of 0.95. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.87 and a quick ratio of 1.51. The company’s fifty day moving average price is $197.17 and its two-hundred day moving average price is $214.35. Danaher has a 52-week low of $180.03 and a 52-week high of $242.80.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, April 21st. The conglomerate reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.94 by $0.12. Danaher had a net margin of 14.89% and a return on equity of 10.96%. The firm had revenue of $5.95 billion for the quarter, compared to analyst estimates of $6 billion. During the same quarter in the previous year, the firm posted $1.88 EPS. The business’s revenue for the quarter was up 3.7% on a year-over-year basis. Danaher has set its FY 2026 guidance at 8.350-8.550 EPS. On average, analysts expect that Danaher will post 8.39 EPS for the current year.

Insider Transactions at Danaher

In related news, EVP Gregory M. Milosevich sold 1,320 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $208.01, for a total transaction of $274,573.20. Following the transaction, the executive vice president owned 5,099 shares in the company, valued at $1,060,642.99. This represents a 20.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 10.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Tyche Wealth Partners LLC acquired a new position in Danaher during the 3rd quarter valued at about $462,000. Bank Pictet & Cie Europe AG lifted its position in Danaher by 25.4% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 366,481 shares of the conglomerate’s stock valued at $83,895,000 after purchasing an additional 74,301 shares during the period. Lockheed Martin Investment Management Co. lifted its position in Danaher by 49.4% during the 3rd quarter. Lockheed Martin Investment Management Co. now owns 25,340 shares of the conglomerate’s stock valued at $5,024,000 after purchasing an additional 8,380 shares during the period. Johnson Investment Counsel Inc. lifted its position in Danaher by 2.9% during the 3rd quarter. Johnson Investment Counsel Inc. now owns 664,705 shares of the conglomerate’s stock valued at $131,784,000 after purchasing an additional 18,744 shares during the period. Finally, Resona Asset Management Co. Ltd. lifted its position in Danaher by 4.6% during the 3rd quarter. Resona Asset Management Co. Ltd. now owns 513,288 shares of the conglomerate’s stock valued at $100,071,000 after purchasing an additional 22,595 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q1 EPS beat and modestly higher FY outlook — Danaher reported $2.06 non‑GAAP EPS (above consensus) and raised FY2026 EPS guidance to $8.35–$8.55, which supports the stock’s fundamental earnings trajectory. Danaher Reports First Quarter 2026 Results
• Positive Sentiment: Bioprocessing and Life Sciences momentum — Management cited strong demand in bioprocessing and life‑sciences tools (double‑digit strength in some businesses), a key driver of beat‑and‑raise dynamics. Reuters: Danaher beats first-quarter profit estimates
• Positive Sentiment: Some analyst support remains — Evercore raised its target to $232 (outperform), indicating pockets of continued buy‑side confidence despite cuts elsewhere. Evercore raises Danaher target
• Neutral Sentiment: €2.98B senior notes offering — Danaher priced €3.0B of euro‑denominated senior notes across several maturities; proceeds boost liquidity (and may fund M&A like Masimo) but add long‑term debt. PR Newswire: Euro‑denominated senior notes offering
• Negative Sentiment: Revenue miss and Diagnostics softness — Revenue rose ~3.7% to $5.95B, below consensus; core revenue growth was modest and Diagnostics (Cepheid/respiratory) was a clear weak spot, which pressured sentiment despite the EPS beat. Yahoo Finance deep dive
• Negative Sentiment: Multiple price‑target cuts — Several firms trimmed targets (JPMorgan, UBS, Guggenheim, Wells Fargo, TD Cowen among others), amplifying near‑term selling pressure even though many retain buy/overweight stances. MarketScreener: JPMorgan target change
• Negative Sentiment: Acquisition/integration and insider selling concerns — Investors are parsing the planned Masimo acquisition and near‑term capital allocation; recent insider sales headlines add to the cautious tone. QuiverQuant analysis

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.